SCHEMBL24253930

SCHEMBL24253930

O=C1CCCC2(CCN(c3nc(-c4ccc(F)cc4)n[nH]3)CC2)N1c1ccc(Cl)c(F)c1

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.33
PDE4A P27815 1/20 0.31
PDE4B Q07343 1/20 0.31
PDE4C Q08493 1/20 0.31
PDE4D Q08499 1/20 0.31
MMP13 P45452 1/20 0.31
JAK2 O60674 1/20 0.30
SYK P43405 1/20 0.30
CYP11B2 P19099 1/20 0.30
PGR P06401 1/20 0.30
NPY5R Q15761 2/20 0.30
HTR1A P08908 1/20 0.30
DRD2 P14416 1/20 0.30
HTR7 P34969 1/20 0.30
RAD51 Q06609 1/20 0.30
HCRTR1 O43613 1/20 0.30
HCRTR2 O43614 1/20 0.30
KCNH2 Q12809 1/20 0.30
LTC4S Q16873 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30424066 1.00 GRM5 (0.33) GRM5PDE4APDE4BPDE4CPDE4D
SCHEMBL30424017 0.80 RAD51 (0.33) MMP13CYP11B2NPY5RRAD51
SCHEMBL30423926 0.78 KDM1A (0.39) SYKCYP11B2RAD51
SCHEMBL24253849 0.78 KDM1A (0.39) SYKCYP11B2RAD51
SCHEMBL30424161 0.77 LMNA (0.35) MMP13CYP11B2RAD51HCRTR1HCRTR2
SCHEMBL24253533 0.77 LMNA (0.35) MMP13CYP11B2RAD51HCRTR1HCRTR2
SCHEMBL24253578 0.76 KMT2A (0.33) MMP13JAK2CYP11B2HTR1ARAD51
SCHEMBL30424099 0.76 KMT2A (0.33) MMP13JAK2CYP11B2HTR1ARAD51
SCHEMBL24253629 0.76 RAD51 (0.33) MMP13CYP11B2RAD51HCRTR1HCRTR2
SCHEMBL24253932 0.76 KCNH2 (0.35) GRM5MMP13CYP11B2RAD51HCRTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof REN, NR3C2, PKD1 GRM5 2306/4885PDE4A 146/4885PDE4B 235/4885
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF REN, NR3C2, PKD1 GRM5 2306/4885PDE4A 146/4885PDE4B 235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.